Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract 1903: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression

Marie N. O'Connor, Ron C. Schackmann, Igor Odintsov, Szabolcs Fatrai, Arie B. Brinkman, Sidney Walker, Jeroen J. Lammerts van Bueren, Cecile A. Geuijen

Cancer Res (2024) 84 (6_Supplement): 1903.

https://doi.org/10.1158/1538-7445.AM2024-1903

Published: 22 March 2024

View articletitled, Abstract 1903: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression

Journal Articles

Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

Igor Odintsov, Ryan C. Cheng, Allan J. Lui, Tom Zhang, Yue C. Lu, Renate I. Kurth, Morana Vojnic, Inna Khodos, Qing Chang, Kevin Chen, Claudio Giuliano, Annalisa Bonifacio, Isao Miyazaki, Elisa de Stanchina, Emanuela Lovati, Marc Ladanyi, Romel Somwar

Cancer Res (2023) 83 (7_Supplement): 4007.

https://doi.org/10.1158/1538-7445.AM2023-4007

Published: 04 April 2023

View articletitled, Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

Journal Articles

Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

Arielle Elkrief, Vladimir Markov, Álvaro Quintanal-Villalonga, Rebecca Caeser, Pawel Sobczuk, Emily Cheng, Alexander Drilon, Gregory J. Riely, William W. Lockwood, Elisa de Stanchina, Charles M. Rudin, Igor Odintsov, Romel Somwar

Cancer Res (2023) 83 (7_Supplement): 6127.

https://doi.org/10.1158/1538-7445.AM2023-6127

Published: 04 April 2023

View articletitled, Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

Journal Articles

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Igor Odintsov, Michael V. Ortiz, Inna Khodos, Marissa S. Mattar, Allan J.W. Lui, Shinji Kohsaka, Elisa de Stanchina, Julia L. Glade Bender, Marc Ladanyi, Romel Somwar

Cancer Res (2022) 82 (6): 1110–1127.

https://doi.org/10.1158/0008-5472.CAN-21-1397

Published: 15 March 2022

View articletitled, CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Includes: Supplementary data

Journal Articles

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

Sudarshan R. Iyer, Igor Odintsov, Adam J. Schoenfeld, Hiroki Sato, Evan Siau, Alexander Drilon, Gregory J. Riely, Romel Somwar, Marc Ladanyi, Monika A. Davare

Cancer Res (2021) 81 (13_Supplement): 1111.

https://doi.org/10.1158/1538-7445.AM2021-1111

Published: 01 July 2021

View articletitled, Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

Journal Articles

Abstract 956: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Igor Odintsov, Inna Khodos, Madelyn Espinosa-Cotton, Allan J. Lui, Marissa Mattar, Alison M. Schram, Ron C. Schackmann, Jeroen Lammerts van Bueren, Cecile A. Geuijen, Elisa de Stanchina, Marc Ladanyi, Romel Somwar

Cancer Res (2021) 81 (13_Supplement): 956.

https://doi.org/10.1158/1538-7445.AM2021-956

Published: 01 July 2021

View articletitled, Abstract 956: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Journal Articles

Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Igor Odintsov, Allan J. Lui, Paul R. Bloom, Morana Vojnic, Shawn Leland, Marc Ladanyi, Romel Somwar

Cancer Res (2021) 81 (13_Supplement): 935.

https://doi.org/10.1158/1538-7445.AM2021-935

Published: 01 July 2021

View articletitled, Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 1903: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression

Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

Abstract 956: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Email alerts

AACR Journals

Update search

Abstract 1903: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression

Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

Abstract 956: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only